Article

New drug approved to treat kidney cancer

Author(s):

It's been a productive few years in kidney cancer for the Food and Drug Administration. Since 2005, the FDA has approved six drugs to treat kidney cancer--three in the past eight months alone, the latest being Votrient (pazopanib).Word came late Monday that the agency approved the oral drug for advanced renal cell carcinoma, only two weeks after a panel that advises the FDA recommended the agency give the drug the green light. (Check out CURE's coverage of the ODAC recommendation.)The other targeted drugs approved for kidney cancer include Sutent (sunitinib), Nexavar (sorafenib), Torisel (temsirolimus), Afinitor (everolimus), which was approved in March, and Avastin (bevacizumab), which received the FDA nod in August.At a conference I attended earlier this year, kidney cancer expert Robert Figlin, MD, made a prediction: Afinitor and Avastin would be approved for kidney cancer in 2009. Check, and check. And within two years, he said, pazopanib would get the thumbs up. I guess the FDA didn't want to wait. By the way, Figlin made another prediction about a drug called axitinib; we'll keep you posted.Read CURE's extensive coverage of the latest in treating kidney cancer in "Reining in Renal Cancer" from the Summer 2009 issue.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of doctor.
Image of man with black hair.
Picture of Dr. Pouneh Razavi
Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population.
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Image of man.
Image of Crispino
Image of Dr. Reznick
Picture of Joy Anderson
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Related Content